SELLAS Life Sciences (SLS) Income from Continuing Operations (2011 - 2026)
SELLAS Life Sciences' (SLS) quarterly Income from Continuing Operations came in at 15053000.0 in Q1 2026, down 140.35% year-on-year from 37307850.81 in Q1 2025, and down 80.17% on a QoQ basis from 8355000.0 in Q4 2025.
SELLAS Life Sciences (SLS) Income from Continuing Operations (2011 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has 14 years of Income from Continuing Operations data on file, last reported at 15053000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 140.35% year-over-year to 15053000.0 in Q1 2026; TTM through Mar 2026 was 39620000.0, a 39.35% decrease from a year earlier, with the FY2025 full-year figure at 51112000.0, up 2.42% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 15053000.0, down from 8355000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for SLS reached as high as 6263000.0 in Q1 2025 and fell as low as 16835000.0 in Q1 2022.
- Historically, Income from Continuing Operations has averaged 9324411.76 across 5 years, with a median of 8723000.0 in 2022.
- Across the five-year window, Income from Continuing Operations sank 617.91% in 2022 and jumped 35.73% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 9646000.0 in 2022, then grew by 14.19% to 8277000.0 in 2023, then gained by 15.21% to 7018000.0 in 2024, then retreated by 19.05% to 8355000.0 in 2025, then tumbled by 80.17% to 15053000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 15053000.0 in Q1 2026, 8355000.0 in Q4 2025, and 7283000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | SELLAS Life Sciences | 1.96 Bn | 1.96 Bn | - | -15.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.05 Mn |
| Dec 31, 2025 | -8.36 Mn |
| Sep 30, 2025 | -7.28 Mn |
| Jun 30, 2025 | -8.93 Mn |
| Mar 31, 2025 | -6.26 Mn |
| Dec 31, 2024 | -7.02 Mn |
| Sep 30, 2024 | -7.43 Mn |
| Jun 30, 2024 | -7.72 Mn |
| Mar 31, 2024 | -9.75 Mn |
| Dec 31, 2023 | -8.28 Mn |
| Sep 30, 2023 | -9.46 Mn |
| Jun 30, 2023 | -9.15 Mn |
| Mar 31, 2023 | -11.38 Mn |
| Dec 31, 2022 | -9.65 Mn |
| Sep 30, 2022 | -7.25 Mn |
| Jun 30, 2022 | -8.72 Mn |
| Mar 31, 2022 | -16.84 Mn |
| Dec 31, 2021 | -11.72 Mn |
| Sep 30, 2021 | -7.08 Mn |
| Jun 30, 2021 | -4.55 Mn |